dc.contributor.author | Heaney, Robert P. | en_US |
dc.contributor.author | Recker, Robert R. | en_US |
dc.contributor.author | Watson, Patrice A. | en_US |
dc.contributor.author | Lappe, Joan M. | en_US |
dc.date.accessioned | 2013-09-18T19:16:53Z | |
dc.date.available | 2013-09-18T19:16:53Z | |
dc.date.issued | 2004-08 | en_US |
dc.identifier.other | NIAMS-115 (National Institute of Arthritis and Musculoskeletal and Skin Diseases) | en_US |
dc.identifier.other | IRB 01-12531 (Creighton University) | en_US |
dc.identifier.other | NCT00074711 (ClinicalTrials.gov) | en_US |
dc.identifier.uri | http://hdl.handle.net/10504/45932 | |
dc.description.abstract | This data has been de-identified to protect the privacy of the research participants. | en_US |
dc.description.abstract | visit (v 0) serum data screen id, sCa mg_dl, sCa 2 DATE, sCa 2 mg_dl, sCa 3 mg_dl, sPi mg_dl, sCrt mg_dl, s uric acid mg/dl | en_US |
dc.description.sponsorship | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | en_US |
dc.format | This was originally an Access database. It was stripped of identifying information and converted into Excel spreadsheets. | en_US |
dc.format | A CSV (text) file was also created from the spreadsheet | en_US |
dc.format.extent | 14 KB xlsx | en_US |
dc.format.extent | 4 KB csv | en_US |
dc.format.mimetype | application/vnd.openxmlformats-officedocument.spreadsheetml.sheet (.xlsx) | en_US |
dc.publisher | Creighton Osteoporosis Research Center | en_US |
dc.relation | This was originally an Access database. It was stripped of identifying information and converted into Excel spreadsheets. | en_US |
dc.subject.other | Data Tables | en_US |
dc.title | v 0 serum | en_US |
dc.title.alternative | visit (v 0) serum data | en_US |
dc.rights.holder | Heaney, Robert P. | en_US |
dc.publisher.location | Omaha, NE | en_US |
dc.title.work | Bone Sparing by Calcium Salts With and Without Extra Phosphorus | en_US |
dc.description.note | Description from ClinicalTrials.gov: Osteoporosis is the most common type of bone disease. Calcium supplements normally used in anti-osteoporosis treatment are calcium salts of carbonate or citrate; however, these salts bind phosphorus from food in the intestine and restrict phosphorus available for bone building. This study will evaluate the efficacy of adding calcium phosphate to a regimen of teriparatide and vitamin D in increasing bone mineral density in women with osteoporosis. It is hypothesized that the group taking the phosphate-containing calcium supplement will have greater gains in bone mineral density (BMD) during the course of the study than the group not receiving phosphate.
All participants will receive teriparatide and vitamin D during the course of the 12-month study. Participants will be randomly assigned to one of two groups. One group will receive calcium phosphate and the other will receive calcium carbonate. BMD will be measured at spine and hip at baseline and at 3, 6, and 12 months of treatment. | en_US |
dc.program.unit | School of Medicine | en_US |
dc.program.unit | Department of Medicine | en_US |
dc.program.unit | Endocrinology | en_US |
dc.program.unit | Osteoporosis | en_US |
dc.contributor.cuauthor | Heaney, Robert P. | en_US |
dc.contributor.cuauthor | Recker, Robert R. | en_US |
dc.contributor.cuauthor | Watson, Patrice A. | en_US |
dc.contributor.cuauthor | Lappe, Joan M. | en_US |
dc.description.note2 | 2004-2008 | |
dc.identifier.grantno | R01 AR048846 (National Institute of Health) | en_US |